{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:28:30Z","timestamp":1792787310118,"version":"4.5.0"},"reference-count":30,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T00:00:00Z","timestamp":1685318400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Bayer Pharmaceuticals"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Stroke Vasc Neurol"],"accepted":{"date-parts":[[2023,5,5]]},"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The optimal time to commence anticoagulation in patients with atrial fibrillation (AF) after ischaemic stroke or transient ischaemic attack (TIA) is unclear, with guidelines differing in recommendations. A limitation of previous studies is the focus on clinically overt stroke, rather than radiologically obvious diffusion-weighted imaging ischaemic lesions. We aimed to quantify silent ischaemic lesions and haemorrhages on MRI at 1\u2009month in patients commenced on early (&lt;4\u2009days) vs late (\u22654\u2009days) anticoagulation. We hypothesised that there would be fewer ischaemic lesions and more haemorrhages in the early anticoagulant group at 1-month MRI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A prospective multicentre, observational cohort study was performed at 11 Australian stroke centres. Clinical and MRI data were collected at baseline and follow-up, with blinded imaging assessment performed by two authors. Timing of commencement of anticoagulation was at the discretion of the treating stroke physician.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We recruited 276 patients of whom 208 met the eligibility criteria. The average age was 74.2 years (SD\u00b110.63), and 79 (38%) patients were female. Median National Institute of Health Stroke Scale score was 5 (IQR 1\u201312). Median baseline ischaemic lesion volume was 5\u2009mL (IQR 2\u201317). There were a greater number of new ischaemic lesions on follow-up MRI in patients commenced on anticoagulation \u22654\u2009days after index event (17% vs 8%, p=0.04), but no difference in haemorrhage rates (22% vs 32%, p=0.10). Baseline ischaemic lesion volume of \u22645\u2009mL was less likely to have a new haemorrhage at 1\u2009month (p=0.02). There was no difference in haemorrhage rates in patients with an initial ischaemic lesion volume of &gt;5\u2009mL, regardless of anticoagulation timing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Commencing anticoagulation &lt;4\u2009days after stroke or TIA is associated with fewer ischaemic lesions at 1\u2009month in AF patients. There is no increased rate of haemorrhage with early anticoagulation. These results suggest that early anticoagulation after mild-to-moderate acute ischaemic stroke associated with AF might be safe, but randomised controlled studies are needed to inform clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/svn-2023-002357","type":"journal-article","created":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T10:00:27Z","timestamp":1685354427000},"page":"30-37","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":15,"title":["Early anticoagulation in patients with stroke and atrial fibrillation is associated with fewer ischaemic lesions at 1 month: the ATTUNE study"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5833-7632","authenticated-orcid":false,"given":"Angelos","family":"Sharobeam","sequence":"first","affiliation":[{"name":"Melbourne Brain Centre at Royal Melbourne Hospital, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longting","family":"Lin","sequence":"additional","affiliation":[{"name":"University of New South Wales South Western Sydney Clinical School, Liverpool, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Lam","sequence":"additional","affiliation":[{"name":"Melbourne Brain Centre at Royal Melbourne Hospital, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8843-5890","authenticated-orcid":false,"given":"Carlos","family":"Garcia-Esperon","sequence":"additional","affiliation":[{"name":"Department of Neurology, John Hunter Hospital, Newcastle, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yash","family":"Gawarikar","sequence":"additional","affiliation":[{"name":"Department of Neurology, Calvary Public Hospital, Canberra, Australian Capital Territory, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronak","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Neurology, Calvary Public Hospital, Canberra, Australian Capital Territory, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Lee-Archer","sequence":"additional","affiliation":[{"name":"Department of Neurology, Northern Hospital Epping, Epping, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Neurology, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia"},{"name":"The University of Queensland School of Medicine, Herston, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Roizman","sequence":"additional","affiliation":[{"name":"Department of Neurology, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia"},{"name":"The University of Queensland School of Medicine, Herston, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Gilligan","sequence":"additional","affiliation":[{"name":"Neurosciences Clinical Institute, Epworth Healthcare, Richmond, Virginia, Australia"},{"name":"Department of Neurology, Austin Health, University of Melbourne, Heidelberg, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Lee","sequence":"additional","affiliation":[{"name":"Flinders University College of Medicine and Public Health, Adelaide, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kee Meng","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Gold Coast University Hospital, Southport, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Day","sequence":"additional","affiliation":[{"name":"The University of Sydney Northern Clinical School, St Leonards, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Levi","sequence":"additional","affiliation":[{"name":"Department of Neurology, John Hunter Hospital, Newcastle, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M","family":"Davis","sequence":"additional","affiliation":[{"name":"Melbourne Brain Centre at Royal Melbourne Hospital, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Parsons","sequence":"additional","affiliation":[{"name":"University of New South Wales South Western Sydney Clinical School, Liverpool, New South Wales, Australia"},{"name":"Department of Neurology and Neurophysiology, Liverpool Hospital, Liverpool, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Yan","sequence":"additional","affiliation":[{"name":"Melbourne Brain Centre at Royal Melbourne Hospital, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,5,29]]},"reference":[{"key":"2025081709375139000_9.1.30.1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-12-200706190-00007"},{"key":"2025081709375139000_9.1.30.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62343-0"},{"key":"2025081709375139000_9.1.30.3","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(18)30356-9"},{"key":"2025081709375139000_9.1.30.4","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000254600.92975.1f"},{"key":"2025081709375139000_9.1.30.5","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1161\/STROKEAHA.119.027569","article-title":"Dabigatran treatment of acute Noncardioembolic ischemic stroke","volume":"51","author":"Butcher","year":"2020","journal-title":"Stroke"},{"key":"2025081709375139000_9.1.30.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310907"},{"key":"2025081709375139000_9.1.30.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561"},{"key":"2025081709375139000_9.1.30.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561"},{"key":"2025081709375139000_9.1.30.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638"},{"key":"2025081709375139000_9.1.30.10","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/2396987319841187","article-title":"Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: a European stroke organization guideline","volume":"4","author":"Klijn","year":"2019","journal-title":"Eur Stroke J"},{"key":"2025081709375139000_9.1.30.11","unstructured":"Intercollegiate Stroke Working Party . National clinical guideline for stroke. 2016. Available: https:\/\/www.rcplondon.ac.uk\/guidelines-policy\/stroke-guidelines [Accessed 31 Jan 2022]."},{"key":"2025081709375139000_9.1.30.12","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0000000000000211"},{"key":"2025081709375139000_9.1.30.13","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw210"},{"key":"2025081709375139000_9.1.30.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.12.039"},{"key":"2025081709375139000_9.1.30.15","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1177\/0891988719862631","article-title":"Preexisting cerebral abnormalities and functional outcomes after acute ischemic stroke","volume":"32","author":"Qu","year":"2019","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"2025081709375139000_9.1.30.16","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac020"},{"key":"2025081709375139000_9.1.30.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022066"},{"key":"2025081709375139000_9.1.30.18","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1111\/ene.15482","article-title":"Prognostic significance of the clinical and radiological Haemorrhagic transformation subtypes in acute ischaemic stroke: a systematic review and meta-analysis","volume":"29","author":"He","year":"2022","journal-title":"Eur J Neurol"},{"key":"2025081709375139000_9.1.30.19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1995.03530130023023"},{"key":"2025081709375139000_9.1.30.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2006.01.015"},{"key":"2025081709375139000_9.1.30.21","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1253\/circj.CJ-14-0793","article-title":"Early administration of non-vitamin K antagonist oral anticoagulants for acute ischemic stroke patients with atrial fibrillation in comparison with warfarin mostly combined with heparin","volume":"79","author":"Nomura","year":"2015","journal-title":"Circ J"},{"key":"2025081709375139000_9.1.30.22","unstructured":"IBM . SPSS Statistics for Windows, version 27. Armonk, N.Y, USA: IBM Corp,"},{"key":"2025081709375139000_9.1.30.23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39335.541782.AD"},{"key":"2025081709375139000_9.1.30.24","doi-asserted-by":"publisher","DOI":"10.7326\/M14-0538"},{"key":"2025081709375139000_9.1.30.25","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamaneurol.2017.2161","article-title":"Phase 2 exploratory clinical study to assess the effects of Xarelto (Rivaroxaban) versus warfarin on ischemia, bleeding, and hospital stay in acute cerebral Infarcts in patients with non-valvular atrial fibrillation (Triple AXEL) study group. Rivaroxaban vs warfarin sodium in the ultra-early period after atrial fibrillation-related mild ischemic stroke: a randomized clinical trial","volume":"74","author":"Hong","year":"2017","journal-title":"JAMA Neurol"},{"key":"2025081709375139000_9.1.30.26","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.107.510321"},{"key":"2025081709375139000_9.1.30.27","unstructured":"Early versus late initiation of direct oral anticoagulants in post-ischemic stroke patients with atrial fibrillation (ELAN): an international, multicentre, randomized-controlled, two-arm, assessor-blinded trial (ELAN). Clinicaltrials.Gov. 2022. Available: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03148457 [Accessed 22 Feb 2022]."},{"key":"2025081709375139000_9.1.30.28","unstructured":"OPTIMAS: optimal timing of anticoagulation after acute ischemic stroke: a randomized controlled trial (OPTIMAS). Clinicaltrials.Gov. 2022. Available: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03759938 [Accessed 22 Feb 2022]."},{"key":"2025081709375139000_9.1.30.29","unstructured":"TIMING of oral anticoagulant therapy in acute ischemic stroke with atrial fibrillation. Clinicaltrials.Gov. 2022. Available: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02961348 [Accessed 22 Feb 2022]."},{"key":"2025081709375139000_9.1.30.30","unstructured":"Optimal delay time to initiate anticoagulation after ischemic stroke in atrial fibrillation (START). Clinicaltrials.Gov. 2022. Available: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03021928 [Accessed 22 Feb 2022]."}],"container-title":["Stroke and Vascular Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/svn-2023-002357","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,17]],"date-time":"2025-08-17T16:37:58Z","timestamp":1755448678000},"score":1,"resource":{"primary":{"URL":"https:\/\/svn.bmj.com\/lookup\/doi\/10.1136\/svn-2023-002357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,29]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,2,27]]},"published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1136\/svn-2023-002357"],"URL":"https:\/\/doi.org\/10.1136\/svn-2023-002357","relation":{},"ISSN":["2059-8688","2059-8696"],"issn-type":[{"value":"2059-8688","type":"print"},{"value":"2059-8696","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,29]]}}}